Burden of Cardiovascular Disease in the U.S. - A Focus on Gender and Ethnic Disparities

Dr. Abena Osei-Wusu, MD, FACC, FSCAI, Medical Director, Atherosclerosis, US Clinical Development and Medical Affairs, Novartis
The Burden of Cardiovascular Disease in the US: a Focus on Gender and Ethnic Disparities

Abena Osei-Wusu, MD, FACC, FSCAI
Medical Director, Atherosclerosis
US Clinical Development and Medical Affairs

This presentation is intended for non-promotional scientific purposes only. Data presented is publicly available information and is accurate at the time of presentation. Novartis will not be responsible for any subsequent use outside the intended purpose or changes to the presentation by you or any third party.
What is cardiovascular disease (CVD)?

- Broad spectrum of diseases involving the heart and blood vessels:
  - Atherosclerosis
  - Coronary heart disease
  - Hypertension
  - Stroke
  - Heart failure
  - Arrhythmia
  - Valvular heart disease
Cardiovascular disease is the leading cause of death in the US*

Cardiovascular disease death trend has reversed in recent years

Deaths attributable to CVD, United States, 1900 to 2017

Limited treatment options

Improvements in care

Stagnation

Adapted with permission from Virani S et al. *Circulation*. 2020;141:e139-e596.
Cardiovascular disease is impactful, but preventable

Approximately 12 million women in the US live with some form of CVD

CVD is the leading cause of death for women in the US

CVD causes 1 in 3 female deaths annually (about one woman every minute)

A substantial proportion of cardiovascular disease can be avoided by addressing key risk factors – cholesterol, high blood pressure, and smoking

CVD, cardiovascular disease
Atherosclerotic Cardiovascular Disease (ASCVD) is the most common form of CVD in the US

- **ASCVD:**
  - Coronary artery disease
    - Angina, heart attack, revascularization
  - Stroke and Transient Ischemic Attack (TIA ‘mini-stroke’)
  - Peripheral arterial disease

- **Impact:**
  - Approximately 30 million patients carry an ASCVD diagnosis

ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease.

**ASCVD is more financially impactful to patients than cancer**

- Financial toxicity occurs more frequently in patients with ASCVD than those with cancer

- Financial toxicity includes:
  - Difficulty paying medical bills
  - Inability to pay bills at all
  - High financial distress
  - Medication nonadherence
  - Food insecurity
  - Delayed/foregone care due to cost

- Patients with both ASCVD and cancer experience compounded impact

ASCVD, atherosclerotic cardiovascular disease
Gender disparities in preventive care for women

Women are less likely to receive adequate treatment/prevention than men

- Physicians underestimate risk in women compared with men
- Guideline-recommended risk calculators may underestimate cardiovascular disease risk in women
- There are differences in symptoms/presentation between men and women

Cardiovascular disease mortality in women

- Leading cause of death for Black and White women
- Approximately 300,000 deaths in 2017
- Approximately 6.2% of women over 20 have coronary artery disease (1 in 16)

CVD, cardiovascular disease
Racial and ethnic disparities in cardiovascular disease

- Underrepresented groups face a higher burden
- Prevalence is higher in Blacks compared to Whites
- Emerging data show lower prevalence and mortality in Hispanic and Latina populations (Hispanic paradox)
- Lower prevalence in Asians compared to Whites
Racial and ethnic disparities in cardiovascular disease

- Non-Hispanic Black people are twice as likely to die from cardiovascular disease than non-Hispanic Asians

- There are substantial differences in the prevalence of risk factors across race and ethnicity

Geographic disparities in cardiovascular disease

Death rate per 100,000 population for cardiovascular disease by state, 2015 to 2017

<table>
<thead>
<tr>
<th>Highest</th>
<th>Lowest</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Death Rate</td>
</tr>
<tr>
<td>Mississippi</td>
<td>308.6</td>
</tr>
<tr>
<td>Alabama</td>
<td>295.3</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>294.6</td>
</tr>
</tbody>
</table>

Mortality due to heart disease is increasing among women <65 years in rural areas, but not among men in rural areas and not in women in metro areas.

Between 1999 and 2017, rural areas exhibited greater cardiovascular disease mortality, with the absolute difference between rural areas and large metropolitan areas nearly doubling over time.

CVD, cardiovascular disease.

Addressing cardiovascular disease risk by targeting risk factors

Population attributable risk in high-income countries

- High cholesterol: 20.7
- Tobacco use: 15.7
- Hypertension: 14.6
- Diabetes: 7.8
- Obesity: 6.8

High cholesterol is an important risk factor for cardiovascular disease

Linear relationship between LDL cholesterol (LDL-C) and cardiovascular disease

Adapted with permission from Ference BA et al.
Gaps in care – suboptimal LDL cholesterol (LDL-C) management

ASCVD patients achieve guideline-recommended LDL-C thresholds of <70 mg/dL despite being eligible for statin therapy

% LDL-C distribution* among patients with ASCVD within certain ACC/AHA statin-eligible groups†

- 20% <70 mg/dL
- 51% 70-99 mg/dL
- 21% 100-129 mg/dL
- 8% >130 mg/dL

Only 20% of patients with ASCVD reach recommended LDL-C goals

Adapted with permission from Wong ND et al.

ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.

*Total estimated N = Weighted N X (total weighted N on statins in each group/weighted N on statins with LDL-C values); total weighted N on statins for each group (in millions); †Results from US National Health and Nutrition Examination Survey 2011-2012 examining statin use and goal attainment in 1677 patients eligible for statin therapy. Of these patients, 43.2% were on statin therapy.

Why do the majority of people have elevated cholesterol?
Prevalence and Number of US Adults Eligible for and Currently Using Statin Therapy by Sex (NHANES 2011-2014)

Guideline implementation is suboptimal

NHANES, National Health and Nutrition Examination Survey

Patients

Percentage of ASCVD patients, according to statin adherence levels*

<table>
<thead>
<tr>
<th>PDC levels</th>
<th>Stratification</th>
<th>Adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Fully adherent</td>
<td>≥80%</td>
</tr>
<tr>
<td>Medium</td>
<td>Partially adherent</td>
<td>≥40% to ≤79%</td>
</tr>
<tr>
<td>Low</td>
<td>Nonadherent</td>
<td>≤40%</td>
</tr>
</tbody>
</table>

*Adherence to therapy is essential

ACEi, angiotensin-converting enzyme inhibitors; ASCVD, atherosclerotic cardiovascular disease; MI, myocardial infarction; PDC, proportions of days covered.
*A large nonconcurrent cohort study was conducted by using 2010 to 2013 medical and pharmaceutical claims obtained from Aetna Commercial and Medicare Advantage population databases (N=14,119 including 4015 post-MI patients and 12,976 patients with ASCVD). Patients were stratified based on adherence using PDCs for statins and ACEi.
Improving cardiovascular disease risk in women and underrepresented groups

Generate the right evidence

- Recognize that one size does not fit all
- Ensure adequate representation of women and underrepresented groups in clinical research

Address barriers to care

- Educate health care providers, patients and policymakers
- Leverage technology to increase quality of care
Legislative call to action

Encourage your state’s health department to update cardiovascular plans to improve your constituents’ cardiovascular health

Engage in partnerships to educate stakeholders on prevention

Develop policies that advance a health care system that equally supports diagnostics and treatments
Thank you